HIV / AIDS

Men who have sex with men who seek out sexual partners online are more likely to report sexually transmitted infections, including syphilis, gonorrhea, and chlamydia.

Men who experienced seroconversion following the advent of antiviral therapy (circa 1996) and who received treatment were found to be more likely to reduce risk behaviors.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A new study suggests that combined antiretroviral treatment in patients with HIV does not prevent viral load rebound in semen after the treatment is paused.

People with HIV display signs of advanced aging when certain biomarkers are studied.

In a plenary at the HIV Research for Prevention conference, Anthony Fauci, MD, discussed the need for implementation of new HIV prevention mechanisms.

It’s time to consider the newly diagnosed population as distinct from the HIV-infected population as a whole when measuring viral suppression levels.

At the HIV Research for Prevention, in Madrid, Spain, the Global HIV Vaccine Enterprise presented a framework for working towards the development of a safe and effective HIV vaccine.

The clinical characteristics and outcomes of Pneumocystis jirovecii pneumonia differ in immunocompromised patients with and without HIV.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Revised DHHS and IAS–USA guidelines provide new insight for physicians managing patients with HIV.

Although Latino women face higher barriers to HIV care than their male counterparts, a willingness to use support services may be a reason they fare equally well.

Three new trials, published in CID, highlight potential for intravaginal rings.

Long-term safety and efficacy data from the pivotal phase 3 EMERALD trial were presented at ID Week 2018.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

New surveillance report sheds light on meningococcal disease rates among HIV-infected MSM.

Plenty of research has gone into the causes and progression of Alzheimer’s disease. Now a new effort aims to make the case that scientists have been looking in the wrong direction.

Colleen Kelley, MD, discusses the possibility of an HIV vaccine and current progress being made in HIV prevention.

Despite big advances in the field of HIV treatment, including streamlined drug regimens that help infected people achieve normal or near-normal lifespans, living with HIV often means dealing with neurocognitive impairment of some kind.

The NIH has launched a phase 1 trial evaluating whether it is safe to administer infusions of 2 broadly neutralizing antibodies (bNAbs) in people living with HIV.

Even as new treatments for the virus become available, access may be an issue thanks to budget re-shuffling in Washington.

As millennials communicate extensively by text, investigators designed a study to improve rates of retention and medication adherence in young men who have sex with men.

Douglas Krakower, MD, explains how predictive models can be used to identify patients that are at a higher risk for HIV and could benefit from learning about PrEP.

Eric Daar, MD, discusses the obstacles associated with new research and technology in the pursuit of finding a cure for HIV.

HIV-specific ex-vivo expanded T cell therapy appears to be safe and well tolerated in people with HIV taking antiretroviral therapy who are virally suppressed.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Local officials tout benefits of needle exchange, testing programs at reducing risk.

An international literature review indicates that 78% of children with multidrug-resistant tuberculosis were successfully treated with second-line treatment.

In a new study, investigators found that providing guidance and advice in people who inject drugs increased use of antiretroviral medication use by 30%.